CGMP/Drugs for Animals/Prepared, Packed or Held Under Insanitary Conditions/Adulterated: FDA Warning Letter to Sciarra Aeromed, Inc., 2026-09-23
Letter issued · posted to fda.gov .
Subject as published: CGMP/Drugs for Animals/Prepared, Packed or Held Under Insanitary Conditions/Adulterated
TL;DR
At a glance: FDA Center for Veterinary Medicine issued a Warning Letter (CMS# 728248, September 23, 2026) to Sciarra Aeromed, Inc. (President Christopher J. Sciarra, Carmel, NY) for manufacturing an adulterated and misbranded sterile animal drug product under insanitary conditions. FDA's multistate investigation and facility inspection (February 9–25, 2026) identified microbiological contamination including five fungal species (Purpureocillium lilacinum, Paraisaria heteropoda, Gongronella lacrispora, Purpureocillium sodanum, Isaria takamizusanensis) in the purportedly sterile product, linked to serious adverse events and deaths; manufacturing deficiencies included absence of sporicidal cleaning agents in ISO 5/7 areas and inadequate environmental monitoring during production.
Argus analysis
# FDA Warning Letter Analysis: Sciarra Aeromed, Inc.
**Company and Violations**
Sciarra Aeromed, Inc., a veterinary pharmaceutical manufacturer located in Carmel, New York, received a Warning Letter from FDA's Center for Veterinary Medicine on September 23, 2026, following a multistate investigation into a product contamination incident. The investigation identified the largest number of deaths associated with a product quality defect in any FDA-regulated veterinary medical product on record, stemming from microbiological contamination of a purportedly sterile injectable product. FDA inspected the facility from February 9–25, 2026, collected and tested numerous samples, and reviewed epidemiological data from over (b)(4) individual cases before issuing the Warning Letter.
**Regulatory Citations and Implications**
The violations center on three primary FD&C Act sections. Section 501(c) addresses adulteration when product strength, purity, or quality falls below labeled claims—here, the product labeled as sterile contained multiple viable fungal species including *Purpureocillium lilacinum*, *Paraisaria heteropoda*, and *Gongronella lacrispora*. Section 501(a)(2)(A) addresses manufacturing under insanitary conditions, which FDA documented through inadequate cleaning procedures, absent sporicidal agents, no environmental monitoring during production, lack of personnel sampling, absence of smoke studies, facility disrepair with pest ingress risks, and improper gowning. Section 502(f)(1) covers misbranding due to inadequate labeling directions for use. These citations reflect serious gaps in current Good Manufacturing Practice (CGMP) controls for sterile injectable products.
**Timeline and Industry Observations**
FDA's post-inspection correspondence was received March 18, 2026. Peer compliance officers in sterile injectable manufacturing should monitor for product recalls, import alerts, and potential consent decrees. The severity of this incident—characterized as causing unprecedented mortality in veterinary medicine—typically precedes heightened regulatory scrutiny across the industry and may prompt FDA guidance updates on environmental monitoring and personnel sampling protocols for animal drug manufacturers.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Sciarra Aeromed, Inc. MARCS-CMS 728248 — September 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Animal & Veterinary Drugs Recipient: Recipient Name Christopher J. Sciarra Recipient Title President Sciarra Aeromed, Inc. 1791 Route 6 Carmel , NY 10512-2121 United States c.sciarra@sciarralabs.com Issuing Office: Center for Veterinary Medicine United States September 23, 2026 WARNING LETTER CMS# 728248 Re: 728248 Dear Mr. Sciarra: This Warning Letter summarizes significant violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) pertaining to (b)(4) . In response to a series of serious adverse events (b)(4) associated with (b)(4) , the United States Food and Drug Administration (FDA) conducted a multistate investigation. As described in more detail below, we collected numerous samples of the product, inspected your manufacturing facility, and reviewed the epidemiological and clinical evidence associated with over (b)(4) individual cases. Our investigation has linked significant contamination of your purportedly sterile product, (b)(4) to this incident, which involved the largest number of deaths in (b)(4) to be associated with a product quality defect in any FDA-regulated medical product for veterinary use. This incident also resulted in the most fatalities in any species to be associated with microbiological contamination of a purportedly sterile FDA-regulated medical product for veterinary use. (b)(4) From February 9, 2026, to February 25, 2026, we inspected your manufacturing facility at 1791 Route 6, Carmel, NY 10512-2121, and issued a Form FDA 483 with our inspectional observations. Our review of the inspectional and related evidence indicates (b)(4) was manufactured under insanitary conditions, rendering it adulterated under the FD&C Act section 501 (a)(2)(A). During our investigation, we collected and analyzed samples and confirmed that (b)(4) (which purports to be sterile) was, in fact, not sterile, and is therefore adulterated under sections 501 (a)(1) and 501 (c) of the FD&C Act and misbranded under section 502(a). We subsequently reviewed (b)(4) labeling and determined that the product is also misbranded under section 502(f)(1) of the FD&C Act because its labeling fails to bear adequate directions for use. For the above reasons, the introduction of adulterated and misbranded (b)(4) into interstate commerce is a violation of section 301 (a) of the FD&C Act, 21 U.S.C. 331 (a). We acknowledged receipt and reviewed below your post-inspection correspondence received on March 18, 2026, in response to Form FDA 483. You can find the FD&C Act and FDA regulations through links on FDA's homepage at www.fda.gov. Microbiological Contamination in a Purportedly Sterile Product Under section 501 of the FD&C Act, "A drug or device shall be deemed to be adulterated ... if ... its strength differs from, or its purity or quality falls below, that which it purports…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Sciarra Aeromed, Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Sciarra Aeromed, Inc. as of 2026-09-29. Argus ingests new FDA enforcement records daily.
- What FDA violations was Sciarra Aeromed, Inc. cited for?
- The FDA Warning Letter to Sciarra Aeromed, Inc. (issuing office: Center for Veterinary Medicine) cites: CGMP/Drugs for Animals/Prepared, Packed or Held Under Insanitary Conditions/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Sciarra Aeromed, Inc.?
- FDA issued the letter (MARCS-CMS 728248) on 2026-09-23 and posted it publicly on fda.gov on 2026-09-29.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). CGMP/Drugs for Animals/Prepared, Packed or Held Under Insanitary Conditions/Adulterated: FDA Warning Letter to Sciarra Aeromed, Inc., 2026-09-23. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-sciarra-aeromed-inc-2026-09-23-cgmp
"CGMP/Drugs for Animals/Prepared, Packed or Held Under Insanitary Conditions/Adulterated: FDA Warning Letter to Sciarra Aeromed, Inc., 2026-09-23." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-sciarra-aeromed-inc-2026-09-23-cgmp.
Argus HQ Research. "CGMP/Drugs for Animals/Prepared, Packed or Held Under Insanitary Conditions/Adulterated: FDA Warning Letter to Sciarra Aeromed, Inc., 2026-09-23." Digital Empire Holdings LLC. Accessed October 3, 2026. https://argushq.ai/fda/warning-letter/fda-wl-sciarra-aeromed-inc-2026-09-23-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_sciarra_aeromed_inc_2026_09_23_cgmp_2026,
title = {CGMP/Drugs for Animals/Prepared, Packed or Held Under Insanitary Conditions/Adulterated: FDA Warning Letter to Sciarra Aeromed, Inc., 2026-09-23},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-sciarra-aeromed-inc-2026-09-23-cgmp},
note = {Accessed: October 3, 2026}
}